These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35403284)

  • 1. Multiple pigmented nevi induced by the combination of encorafenib and cetuximab in a colon cancer patient.
    Omori R; Miyagaki T; Miyano K; Hashimoto Y; Kadono T
    J Dermatol; 2022 Aug; 49(8):e264-e265. PubMed ID: 35403284
    [No Abstract]   [Full Text] [Related]  

  • 2. Overcoming acquired MET amplification after encorafenib-cetuximab in BRAF-V600E mutated colorectal cancer.
    Ros J; Elez E
    Eur J Cancer; 2022 Sep; 172():326-328. PubMed ID: 35820242
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer.
    Stammler R; Gallois C; Taieb J; Duong JP; Karras A; Thervet E; Lazareth H
    Eur J Cancer; 2021 Apr; 147():60-62. PubMed ID: 33618199
    [No Abstract]   [Full Text] [Related]  

  • 4. [New drug approval: Encorafenib-metastatic colorectal cancers with BRAF V600E mutation after systemic chemotherapy].
    Boilève A; Samalin E
    Bull Cancer; 2020 Nov; 107(11):1086-1088. PubMed ID: 33046237
    [No Abstract]   [Full Text] [Related]  

  • 5. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic
    van Geel RMJM; Tabernero J; Elez E; Bendell JC; Spreafico A; Schuler M; Yoshino T; Delord JP; Yamada Y; Lolkema MP; Faris JE; Eskens FALM; Sharma S; Yaeger R; Lenz HJ; Wainberg ZA; Avsar E; Chatterjee A; Jaeger S; Tan E; Maharry K; Demuth T; Schellens JHM
    Cancer Discov; 2017 Jun; 7(6):610-619. PubMed ID: 28363909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAF
    Stintzing S; Seufferlein T; Rosé C; Reichenbach F; Lüftner D
    Clin Colorectal Cancer; 2022 Sep; 21(3):244-251. PubMed ID: 35654691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E-mutated metastatic colon cancer.
    El-Khoury R; Hafliger E; Gallois C; Louafi S; Garinet S; Zaanan A; Taieb J
    Eur J Cancer; 2021 Jul; 152():1-3. PubMed ID: 34058699
    [No Abstract]   [Full Text] [Related]  

  • 8. Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer.
    Meneguzzo A; Lazzarotto A; Alaibac M
    In Vivo; 2020; 34(1):441-445. PubMed ID: 31882511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation.
    Al-Salama ZT
    Drugs; 2021 May; 81(7):849-856. PubMed ID: 33914242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encorafenib (Braftovi) for metastatic colorectal cancer.
    Med Lett Drugs Ther; 2021 Jan; 63(1616):15-16. PubMed ID: 33512348
    [No Abstract]   [Full Text] [Related]  

  • 11. Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases.
    Alfallouji Y; Spencer A; Calonje E; Perrett CM; Watchorn R; Borysiewicz C; Hodgkinson T; Wasan H; Bunker CB; Sidwell RU
    Clin Exp Dermatol; 2022 Oct; 47(10):1857-1858. PubMed ID: 35633107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy.
    Trullas A; Delgado J; Koenig J; Fuerstenau U; Dedorath J; Hausmann S; Stock T; Enzmann H; Pignatti F
    ESMO Open; 2021 Feb; 6(1):100031. PubMed ID: 33422765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With
    Van Cutsem E; Huijberts S; Grothey A; Yaeger R; Cuyle PJ; Elez E; Fakih M; Montagut C; Peeters M; Yoshino T; Wasan H; Desai J; Ciardiello F; Gollerkeri A; Christy-Bittel J; Maharry K; Sandor V; Schellens JHM; Kopetz S; Tabernero J
    J Clin Oncol; 2019 Jun; 37(17):1460-1469. PubMed ID: 30892987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer.
    Giuliani J; Mantoan B; Bonetti A
    J Oncol Pharm Pract; 2022 Jan; 28(1):199-202. PubMed ID: 34581610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fewer cetuximab-related skin-toxicities in colorectal cancer patients treated with encorafenib: a Yin and Yang effect of ERK paradoxical activation.
    Ciccolini J; Milano G
    Ann Oncol; 2022 Sep; 33(9):981-982. PubMed ID: 35718337
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.
    Tabernero J; Velez L; Trevino TL; Grothey A; Yaeger R; Van Cutsem E; Wasan H; Desai J; Ciardiello F; Yoshino T; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
    ESMO Open; 2021 Dec; 6(6):100328. PubMed ID: 34896698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encorafenib, Binimetinib, and Cetuximab in
    Kopetz S; Grothey A; Yaeger R; Van Cutsem E; Desai J; Yoshino T; Wasan H; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Pfeiffer P; Orlov S; Lonardi S; Elez E; Kim TW; Schellens JHM; Guo C; Krishnan A; Dekervel J; Morris V; Calvo Ferrandiz A; Tarpgaard LS; Braun M; Gollerkeri A; Keir C; Maharry K; Pickard M; Christy-Bittel J; Anderson L; Sandor V; Tabernero J
    N Engl J Med; 2019 Oct; 381(17):1632-1643. PubMed ID: 31566309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eruptive melanocytic nevi associated with encorafenib and cetuximab combination therapy.
    Mikami H; Akasaka E; Nakano H; Sawamura D
    J Dermatol; 2023 May; 50(5):e173-e174. PubMed ID: 36585744
    [No Abstract]   [Full Text] [Related]  

  • 19. Encorafenib, binimetinib and cetuximab combined therapy for patients with
    Huijberts SC; van Geel RM; Bernards R; Beijnen JH; Steeghs N
    Future Oncol; 2020 Feb; 16(6):161-173. PubMed ID: 32027186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.
    Li S; Hu H; Ding D; Zhu Y; Huang J
    Adv Ther; 2021 Mar; 38(3):1650-1659. PubMed ID: 33569738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.